Answers are grounded in this paper and cite their sources.
Background: Peptic ulcer disease (PUD) is a prevalent gastrointestinal disorder worldwide, characterized by damage to the protective mucosal lining of the stomach and duodenum. Its development is primarily associated with Helicobacter pylori infection, prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs), and increased oxidative stress. Although conventional treatments, including proton pump inhibitors (PPIs) and histamine-2 receptor antagonists, are widely used and generally effective, their prolonged administration may be associated with adverse effects, antimicrobial resistance, and disease recurrence. These limitations have encouraged researchers to explore safer and more biologically derived therapeutic alternatives. Objective: This review aims to examine recent scientific evidence regarding the therapeutic potential of medicinal plants in the prevention and treatment of peptic ulcer disease, with particular emphasis on their phytochemical constituents and underlying pharmacological mechanisms. Methods: Relevant scientific publications from the past two decades were reviewed using electronic databases, including PubMed, ScienceDirect, Google Scholar, and Scopus. The review considers experimental findings from in vitro and in vivo studies, along with available clinical evidence concerning the gastroprotective and anti-ulcer properties of medicinal plants. Results: Several medicinal plants, including Glycyrrhiza glabra, Curcuma longa, Zingiber officinale, and Aloe vera, have demonstrated promising gastroprotective and ulcer-healing effects. Their biological activities are largely attributed to the presence of phytochemicals such as flavonoids, tannins, polyphenols, and terpenoids. These compounds may protect the gastric mucosa through several mechanisms, including the regulation of gastric acid secretion, enhancement of mucus and bicarbonate production, reduction of reactive oxygen species (ROS), inhibition of inflammatory mediators such as tumour necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), and antimicrobial effects against H. pylori. Some herbal preparations have also demonstrated favourable tolerability in experimental studies, although their comparative safety requires further clinical investigation. Conclusion: Medicinal plants offer considerable potential as sources of bioactive compounds for developing new gastroprotective and anti-ulcer therapies. Nevertheless, their clinical application remains restricted by insufficient large-scale clinical investigations, variations in extraction and formulation procedures, and limited long-term toxicity data. Further research should focus on standardized herbal formulations, pharmacokinetic and bioavailability studies, well-controlled clinical trials, and possible interactions between herbal products and conventional medicines.
No takes yet. Share an insight, caveat, or question.
Ahire et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: